Newark, New Castle, USA, April 28, 2023 (GLOBE NEWSWIRE) -- According to a recent Growth Plus Reports study the is expected to register a revenue CAGR of 5.73%. The report analyzes the vital strategies, factors, competitive landscape, industry trends, market dynamics, data and forecasts, and ideal investment regions.

Key Takeaways:

· Increased prevalence of autoimmune diseases will drive the market's revenue growth.

· North America to register the fastest-revenue growth in the global Golimumab market.

· Increasing public awareness about the diagnosis and treatment of autoimmune diseases will fuel the market's growth. 

Download Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/golimumab-market/8828

                                         Golimumab Market Scope

Report AttributeDetails
CAGR5.73%
Base Year for Estimation2022
Forecast Period2023 to 2031
Historical Year2021
Segments CoveredIndications, Distribution Channel, and Region
Regional ScopeNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Market Drivers

The increasing prevalence of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, is driving the revenue growth of the global Golimumab market. Furthermore, increased demand for golimumab and other biologic medications, increasing public awareness about autoimmune diseases, the rising geriatric population, and improved diagnosis and treatment contribute to the market's revenue growth rate. 

Market Segmentation

Growth Plus Reports has analyzed the global Golimumab market from three perspectives: Indications, Distribution Channel, and Region.

Indications Segmentation: Based on the indication, the Golimumab market is segmented into rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The rheumatoid arthritis segment dominates the market with the largest revenue share because of the global prevalence of rheumatoid arthritis and the growing acceptance of golimumab as a preferred therapy option due to its effectiveness and safety profile.

Distribution Channel Segmentation: Based on the distribution channel, the Golimumab market is segmented into acute hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominates the market due to the presence of experienced healthcare experts at hospital pharmacies who can provide patients with personalized drugs and dose recommendations.

Regional Growth Dynamics

The global Golimumab market is segmented based on the region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the global Golimumab market with the largest revenue share. The dominance of North America is attributed to the increasing prevalence of autoimmune disorders, the rising need for biologics, the availability of modern healthcare infrastructure, favorable reimbursement policies, and the presence of leading market players in this region.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/golimumab-market/8828

Competitive Landscape

The prominent players in the global Golimumab market are:

· Pfizer, Inc.

· Zydus Cadila Healthcare Ltd.

· Sanofi Aventis Pharma India 

· Teva Pharmaceuticals 

· Merck & Co. 

· Wockhardt Ltd.

· Lyka Hetero Labs

· Jagsonpal Pharmaceuticals Limited

· ACS Dobfar S.p.A.

· Viatris Inc.

The Golimumab market is extremely competitive, with many multinational companies involved. Market leaders participate in mergers, collaborations, acquisitions, and strategic partnerships to enhance their market share and launch new drugs and products.

Recent developments:

· Bio-Thera Solutions, Ltd., announced in October 2021 that it has signed a licensing and supply agreement with Pharmapark LLC for BAT2206, under which Pharmapark will own the exclusive rights to distribute and market the drug in Russia and other CIS countries.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL GOLIMUMAB MARKET- ANALYSIS & FORECAST, BY INDICATIONS
    1. Rheumatoid Arthritis
    2. Psoriatic Arthritis
    3. Ankylosing Spondylitis
  6. GLOBAL GOLIMUMAB MARKET- ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
    1. Hospital Pharmacies             
    2. Retail Pharmacies     
    3. Online Pharmacies 

GOLIMUMAB MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8828

VALUE PROPOSITIONS RELATED TO THE REPORT:

CUSTOMIZATION OPTIONS:

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at - https://www.growthplusreports.com/report-store

Browse Latest Healthcare Related Reports:

Veterinary Telehealth Market by Animal Type (Farm Animals, Companion Animals), Service Type (Teleconsulting, Telemonitoring) – Global Outlook & Forecast 2023-2031

Wheelchair Market by Type (Manual and Powered), Application (Standard Wheelchair, Bariatric Wheelchair), End User (Personal Use and Institutional Use) – Global Outlook & Forecast 2023-2031

Pharmaceutical Suppositories Market by Type (Rectal Suppositories, Vaginal Suppositories), Base (Fatty Base, Water Miscible Base), Distribution Channel (Hospitals, Ambulatory Surgery Centers) – Global Outlook & Forecast 2023-2031

Neovascular Age-related Macular Degeneration Market by Indications (Lucentis, Beovu), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), - Global Outlook and Forecast 2023-2031

Hepatorenal Syndrome Market by Treatment (Therapeutics, Surgical Treatment), Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), End User (Hospitals & Clinics, Ambulatory Surgical Centers) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.